2-amino-2-(4-bromo-phenyl)-ethanesulfonic acid | 98489-03-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-amino-2-(4-bromo-phenyl)-ethanesulfonic acid
• 英文别名: 2-Amino-2-(4-brom-phenyl)-aethansulfonsaeure；I(2)-Amino-4-bromobenzeneethanesulfonic acid；2-amino-2-(4-bromophenyl)ethanesulfonic acid
• CAS: 98489-03-3
• 化学式: C₈H₁₀BrNO₃S
• 分子量: 280.142
• InChiKey: RIGBCMPQQXVRET-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.9
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  88.8
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Methods and compositions for the treatment of amyloid-and epileptogenesis-associated diseases
  申请人：Kong Xianqi

  公开号：US20050038000A1

  公开（公告）日：2005-02-17

  Methods of treating or preventing an amyloid-related disease in a subject by administering to a subject a therapeutic amount of a compound of the invention are described. Also included are methods for inhibiting epileptogenesis in a subject, by administering to a subject an effective amount of an anti-epileptogenic agent. Methods for treating a subject suffering from an epileptogenesis-associated condition, by administering to the subject an effective amount of an anti-epileptogenic agent are also included. Methods for treating convulsions in a subject by administering to the subject an effective amount of a therapeutic amount of a compound of the invention are also described.

  本文描述了通过向患者施用本发明化合物的治疗量来治疗或预防与淀粉样疾病有关的疾病的方法。还包括通过向患者施用抗癫痫剂的有效剂量来抑制癫痫发生的方法。本文还包括通过向患有癫痫发生相关疾病的患者施用抗癫痫剂的有效剂量来治疗患者的方法。本文还描述了通过向患者施用本发明化合物的治疗量的有效剂量来治疗患者的惊厥的方法。
• TREATMENT OF AMYLOID- AND EPILEPTOGENESIS-ASSOCIATED DISEASES
  申请人：Neurochem (International) Limited

  公开号：EP1635909A2

  公开（公告）日：2006-03-22
• [EN] METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOID- AND EPILEPTOGENESIS-ASSOCIATED DISEASES<br/>[FR] PROCEDES ET COMPOSITIONS POUR LE TRAITEMENT DE MALADIES ASSOCIEES AU PEPTIDE AMYLOIDE ET A L'EPILEPTOGENESE
  申请人：NEUROCHEM INT LTD

  公开号：WO2005000406A2

  公开（公告）日：2005-01-06

  Methods of treating or preventing an amyloid-related disease in a subject by administering to a subject a therapeutic amount of a compound of the invention are described. Also included are methods for inhibiting epileptogenesis in a subject, by administering to a subject an effective amount of an anti-epileptogenic agent. Methods for treating a subject suffering from an epileptogenesis-associated condition, by administering to the subject an effective amount of an anti-epileptogenic agent are also included. Methods for treating convulsions in a subject by administering to the subject an effective amount of a therapeutic amount of a compound of the invention are also described.